Novartis Ag (NVS) EBT Margin Growth (1y) (2010 - 2024)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Margin Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
1,755.00 |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-3,737.00 |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
-552.00 |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-5,950.00 |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-3.00 |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
1,234.00 |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
372.00 |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
168.00 |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2024 |
2,064.00 |
| Dec 31, 2023 |
-183,136.00 |
| Jun 30, 2023 |
-1,025.00 |
| Mar 31, 2023 |
-7,133.00 |
| Dec 31, 2022 |
184,055.00 |
| Sep 30, 2022 |
-3,704.00 |
| Jun 30, 2022 |
-355.00 |
| Mar 31, 2022 |
4,860.00 |
| Dec 31, 2021 |
-201,434.00 |
| Sep 30, 2021 |
3,029.00 |
| Jun 30, 2021 |
-8.00 |
| Mar 31, 2021 |
10,175.00 |
| Mar 31, 2020 |
-13,117.00 |
| Mar 31, 2019 |
-8,341.00 |
| Dec 31, 2018 |
-4,124.00 |
| Sep 30, 2018 |
-7,553.00 |
| Jun 30, 2018 |
-117,001.00 |
| Dec 31, 2017 |
23,797.00 |
| Sep 30, 2017 |
2,338.00 |
| Jun 30, 2017 |
84,728.00 |
| Dec 31, 2016 |
-55,940.00 |
| Sep 30, 2016 |
-10,620,689.66 Bn |
| Mar 31, 2016 |
9.79 Bn |
| Dec 31, 2015 |
-6,025.00 |
| Sep 30, 2015 |
10,620,689.66 Bn |
| Mar 31, 2015 |
-46,725.00 |
| Dec 31, 2010 |
-9.03 Bn |
| Jun 30, 2010 |
-1.92 Mn |
